Please login to the form below

How scenario testing helped assess demand for a brand launch in the fragmented NSCLC market


Our client was developing a new drug aimed at first line NSCLC patients. Ahead of its launch they wanted to assess likely uptake in an already fragmented market space led by established 1st generation tyrosine kinase inhibitors (TKIs). There were several scenarios that the client wanted to test, including impact of launch order and the impact of future 3rd generation TKIs on the drug’s market potential. The research was complicated by the fact that both the clients (and likely key future competitors’), profile was as yet unknown – the research therefore needed to assess likely share while taking account of multiple moving parts...

Read the full case study: 
https://bit.ly/2GG0jh2


29th March 2018

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Live webinar: Influencing HCP behaviours – Is now the perfect opportunity?
Putting behavioural science at the forefront of market research
Research Partnership
Quantitative specialist joins Research Partnership, London
Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London
Research Partnership
Webcast
Amplifying the patient voice: How to conduct patient research sensitively to uncover emotional insights
Research Partnership
Webcast
The power of a good story: Turn your insights into effective storytelling with data visualisation
Research Partnership
Article
How will COVID-19 affect uptake of vaccinations against other diseases?
Research Partnership
Podcast
Living With Chronic Illness (Series one)
Research Partnership